BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 31640765)

  • 1. Targeting tauopathy with engineered tau-degrading intrabodies.
    Gallardo G; Wong CH; Ricardez SM; Mann CN; Lin KH; Leyns CEG; Jiang H; Holtzman DM
    Mol Neurodegener; 2019 Oct; 14(1):38. PubMed ID: 31640765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
    Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
    Sydow A; Mandelkow EM
    Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.
    Wheeler JM; McMillan PJ; Hawk M; Iba M; Robinson L; Xu GJ; Dombroski BA; Jeong D; Dichter MA; Juul H; Loomis E; Raskind M; Leverenz JB; Trojanowski JQ; Lee VM; Schellenberg GD; Kraemer BC
    Acta Neuropathol Commun; 2015 Jun; 3():33. PubMed ID: 26041339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.
    Reilly P; Winston CN; Baron KR; Trejo M; Rockenstein EM; Akers JC; Kfoury N; Diamond M; Masliah E; Rissman RA; Yuan SH
    Neurobiol Dis; 2017 Oct; 106():222-234. PubMed ID: 28610892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
    Helboe L; Egebjerg J; Barkholt P; Volbracht C
    Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model.
    Cook C; Kang SS; Carlomagno Y; Lin WL; Yue M; Kurti A; Shinohara M; Jansen-West K; Perkerson E; Castanedes-Casey M; Rousseau L; Phillips V; Bu G; Dickson DW; Petrucelli L; Fryer JD
    Hum Mol Genet; 2015 Nov; 24(21):6198-212. PubMed ID: 26276810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
    Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M
    Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sources of extracellular tau and its signaling.
    Avila J; Simón D; Díaz-Hernández M; Pintor J; Hernández F
    J Alzheimers Dis; 2014; 40 Suppl 1():S7-S15. PubMed ID: 24531154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.
    Congdon EE; Lin Y; Rajamohamedsait HB; Shamir DB; Krishnaswamy S; Rajamohamedsait WJ; Rasool S; Gonzalez V; Levenga J; Gu J; Hoeffer C; Sigurdsson EM
    Mol Neurodegener; 2016 Aug; 11(1):62. PubMed ID: 27578006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A seeding based cellular assay of tauopathy.
    Xu Y; Martini-Stoica H; Zheng H
    Mol Neurodegener; 2016 Apr; 11():32. PubMed ID: 27112488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with Sarkosyl insoluble PHF-tau decrease neurofibrillary tangles formation in aged tau transgenic mouse model: a pilot study.
    Ando K; Kabova A; Stygelbout V; Leroy K; Heraud C; Frédérick C; Suain V; Yilmaz Z; Authelet M; Dedecker R; Potier MC; Duyckaerts C; Brion JP
    J Alzheimers Dis; 2014; 40 Suppl 1():S135-45. PubMed ID: 24614899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
    Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
    Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of spleen tyrosine kinase and tau phosphorylated at tyrosine 18 in a mouse model of tauopathy and in the human hippocampus.
    Köhler C; Fuhr V; Dinekov M
    Brain Res; 2017 Dec; 1677():1-13. PubMed ID: 28919467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central role for p62/SQSTM1 in the elimination of toxic tau species in a mouse model of tauopathy.
    Ono M; Komatsu M; Ji B; Takado Y; Shimojo M; Minamihisamatsu T; Warabi E; Yanagawa T; Matsumoto G; Aoki I; Kanaan NM; Suhara T; Sahara N; Higuchi M
    Aging Cell; 2022 Jul; 21(7):e13615. PubMed ID: 35662390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau oligomers as potential targets for early diagnosis of tauopathy.
    Sahara N; Ren Y; Ward S; Binder LI; Suhara T; Higuchi M
    J Alzheimers Dis; 2014; 40 Suppl 1():S91-6. PubMed ID: 24595194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Truncated Tau Induces Mature Neurofibrillary Pathology in a Mouse Model of Human Tauopathy.
    Zimova I; Brezovakova V; Hromadka T; Weisova P; Cubinkova V; Valachova B; Filipcik P; Jadhav S; Smolek T; Novak M; Zilka N
    J Alzheimers Dis; 2016 Sep; 54(2):831-43. PubMed ID: 27567836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy.
    Iba M; Guo JL; McBride JD; Zhang B; Trojanowski JQ; Lee VM
    J Neurosci; 2013 Jan; 33(3):1024-37. PubMed ID: 23325240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
    Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
    J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.